Pulmonary Langerhans cell histiocytosis
smoking-related cysts · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Pulmonary Langerhans cell histiocytosis is a smoking-related cystic and nodular lung disease of young adults, with characteristic upper/mid-zone nodules evolving to bizarre-shaped cysts. Smoking cessation is central and often leads to stabilisation or regression.
Red flags
- Recurrent pneumothorax
- Development of pulmonary hypertension
- Multisystem involvement (diabetes insipidus, bone lesions)
- Rapid functional decline
Assessment
Differential diagnosis
- Lymphangioleiomyomatosis
- Centrilobular emphysema
- Sarcoidosis
- Metastatic disease / miliary nodules
- Hypersensitivity pneumonitis
Investigations
- HRCT chest (upper/mid-zone nodules and irregular/bizarre-shaped cysts, sparing costophrenic angles)
- Lung function (variable; reduced DLCO common)
- Smoking history (almost universal)
- BRAF V600E and related testing in selected/multisystem disease
- Lung biopsy when the diagnosis is uncertain
- Screen for extrapulmonary involvement (bone, diabetes insipidus)
Management
- Suspect in a young adult smoker with upper-zone nodular/cystic lung disease
- Confirm with characteristic HRCT; biopsy only if atypical
- Assess physiology and screen for pulmonary hypertension
- Strongly advise and support complete smoking cessation
- Monitor for radiological and functional stabilisation/regression after cessation
- Assess for multisystem Langerhans cell histiocytosis and molecular drivers
- Consider systemic/targeted therapy for progressive or multisystem disease
- Manage pneumothorax (recurrent) with definitive intervention
- Treat pulmonary hypertension with specialist input if it develops
- Refer progressive respiratory failure for transplant assessment
Drugs & doses
No lung-specific drug for isolated disease — smoking cessation is primary
Smoking-cessation pharmacotherapy (NRT, varenicline)
Cladribine or targeted therapy (e.g. BRAF/MEK inhibitors) for progressive/multisystem disease
Pulmonary hypertension-targeted therapy at expert centres if indicated
Disposition
Respiratory / ILD clinic; smoking-cessation support; haematology input for multisystem disease; transplant for advanced disease.
Complications & pitfalls
- Recurrent pneumothorax
- Pulmonary hypertension (often out of proportion)
- Progressive cystic lung destruction and respiratory failure
- Extrapulmonary disease progression
Exam pearls
- Nodules that cavitate into bizarre cysts with upper-zone predominance and costophrenic sparing are classic
- Almost all patients are current or former smokers — cessation can reverse disease
- Pulmonary hypertension is common and disproportionate to lung function
- Consider molecular testing (BRAF) in progressive or multisystem disease
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.